Literature DB >> 11529486

Intercellular adhesion molecule-I (ICAM-I, CD54) deficiency segregates the unique pathophysiological requirements for generating idiopathic pneumonia syndrome (IPS) versus graft-versus-host disease following allogeneic murine bone marrow transplantation.

A Panoskaltsis-Mortari1, J R Hermanson, I Y Haddad, O D Wangensteen, B R Blazar.   

Abstract

Following allogeneic bone marrow transplantation (alloBMT), idiopathic pneumonia syndrome (IPS) and graft-versus-host disease (GVHD) caused by donor cell alloreactivity remain major obstacles to a successful outcome. Intercellular adhesion molecule-1 (ICAM-1) is an adhesion molecule that is involved in regulating lymphohematopoietic cell migration and facilitating T-cell responses. To determine whether ICAM-1 expression in the host would affect IPS or GVHD tissue injury responses, ICAM-1(-/-) mice were compared with ICAM-1(+/+) controls. ICAM-1(-/-) recipients did not exhibit the manifestations of IPS injury such as an increase in lung weights nor decreased lung function. The influx of T cells, macrophages, and neutrophils was dramatically dampened as was the production of the inflammatory cytokines interferon-gamma and tumor necrosis factor alpha and the chemokines monocyte chemotactic protein 1, macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and lymphotactin, normally upregulated in the lung during IPS. In contrast, systemic levels of these mediators were unaffected and GVHD-induced lesions in the liver and colon did not differ in severity regardless of ICAM-1 expression. GVHD-mediated mortality was accelerated in ICAM-1(-/-) recipients at doses of allogeneic spleen cells that are otherwise not uniformally lethal. These data implicate ICAM-1 as playing a critical role in the generation of IPS; therefore, ICAM-1 may be a discerning element, segregating IPS from GVHD injury post-alloBMT.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11529486     DOI: 10.1053/bbmt.2001.v7.pm11529486

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  9 in total

1.  A call to arms: a critical need for interventions to limit pulmonary toxicity in the stem cell transplantation patient population.

Authors:  Sabarinath Venniyil Radhakrishnan; Gerhard C Hildebrandt
Journal:  Curr Hematol Malig Rep       Date:  2015-03       Impact factor: 3.952

Review 2.  An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome.

Authors:  Angela Panoskaltsis-Mortari; Matthias Griese; David K Madtes; John A Belperio; Imad Y Haddad; Rodney J Folz; Kenneth R Cooke
Journal:  Am J Respir Crit Care Med       Date:  2011-05-01       Impact factor: 21.405

3.  Targeting the Canonical Nuclear Factor-κB Pathway with a High-Potency IKK2 Inhibitor Improves Outcomes in a Mouse Model of Idiopathic Pneumonia Syndrome.

Authors:  Kenneth A Fowler; Corey M Jania; Stephen L Tilley; Angela Panoskaltsis-Mortari; Albert S Baldwin; Jonathan S Serody; James M Coghill
Journal:  Biol Blood Marrow Transplant       Date:  2017-02-01       Impact factor: 5.742

Review 4.  Leukocyte migration and graft-versus-host disease.

Authors:  Christian A Wysocki; Angela Panoskaltsis-Mortari; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2005-02-08       Impact factor: 22.113

5.  Gas6 deficiency in recipient mice of allogeneic transplantation alleviates hepatic graft-versus-host disease.

Authors:  Laurent Burnier; François Saller; Linda Kadi; Anne C Brisset; Rocco Sugamele; Lucie Baudino; Françoise Bono; Jean-Marc Herbert; Peter Carmeliet; Marc Schapira; Shozo Izui; Anne Angelillo-Scherrer
Journal:  Blood       Date:  2010-02-04       Impact factor: 22.113

6.  A role for TNF receptor type II in leukocyte infiltration into the lung during experimental idiopathic pneumonia syndrome.

Authors:  Gerhard C Hildebrandt; Krystyna M Olkiewicz; Leigh Corrion; Shawn G Clouthier; Elizabeth M Pierce; Chen Liu; Kenneth R Cooke
Journal:  Biol Blood Marrow Transplant       Date:  2008-04       Impact factor: 5.742

7.  Preventive usage of broad spectrum chemokine inhibitor NR58-3.14.3 reduces the severity of pulmonary and hepatic graft-versus-host disease.

Authors:  Sandra Miklos; Gunnar Mueller; Yayi Chang; Abdellatif Bouazzaoui; Elena Spacenko; Thomas E O Schubert; David J Grainger; Ernst Holler; Reinhard Andreesen; Gerhard C Hildebrandt
Journal:  Int J Hematol       Date:  2009-03-14       Impact factor: 2.490

8.  Beta2 integrins separate graft-versus-host disease and graft-versus-leukemia effects.

Authors:  Yaming Liang; Chen Liu; Julie Y Djeu; Bin Zhong; Thorsten Peters; Karin Scharffetter-Kochanek; Claudio Anasetti; Xue-Zhong Yu
Journal:  Blood       Date:  2007-10-10       Impact factor: 22.113

Review 9.  Pulmonary Toxicity After Total Body Irradiation - Critical Review of the Literature and Recommendations for Toxicity Reporting.

Authors:  Jennifer Vogel; Susanta Hui; Chia-Ho Hua; Kathryn Dusenbery; Premavarthy Rassiah; John Kalapurakal; Louis Constine; Natia Esiashvili
Journal:  Front Oncol       Date:  2021-08-26       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.